NASDAQ:EYPT - EyePoint Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $17.63
  • Forecasted Upside: 113.90 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.04 (0.49%)

This chart shows the closing price for EYPT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New EyePoint Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EYPT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EYPT

Analyst Price Target is $17.63
▲ +113.90% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for EyePoint Pharmaceuticals in the last 3 months. The average price target is $17.63, with a high forecast of $25.00 and a low forecast of $8.50. The average price target represents a 113.90% upside from the last price of $8.24.

This chart shows the closing price for EYPT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in EyePoint Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/21/2021HC WainwrightReiterated RatingBuy$15.00Low
7/9/2021HC WainwrightReiterated RatingBuy$15.00Medium
7/2/2021HC WainwrightReiterated RatingBuy$15.00Low
5/26/2021HC WainwrightReiterated RatingBuy$15.00High
5/6/2021HC WainwrightLower Price TargetBuy$16.00 ➝ $15.00High
3/1/2021CowenInitiated CoverageOutperform$25.00Low
1/29/2021HC WainwrightReiterated RatingBuy$16.00Medium
1/27/2021Cantor FitzgeraldInitiated CoverageOverweight$22.00High
1/12/2021B. RileyBoost Price TargetBuy$5.00 ➝ $8.50High
10/9/2020HC WainwrightUpgradeNeutral ➝ Buy$20.00High
8/6/2020HC WainwrightReiterated RatingHoldHigh
4/6/2020B. RileyDowngradeBuy ➝ Neutral$40.00 ➝ $10.00High
4/2/2020HC WainwrightReiterated RatingHoldHigh
3/3/2020HC WainwrightReiterated RatingHoldLow
2/4/2020HC WainwrightReiterated RatingHoldHigh
1/24/2020HC WainwrightReiterated RatingHoldLow
11/11/2019HC WainwrightDowngradeBuy ➝ NeutralHigh
11/5/2019HC WainwrightReiterated RatingBuy$45.00Low
11/4/2019LaidlawInitiated CoverageBuy$50.00High
9/25/2019HC WainwrightReiterated RatingBuy$45.00Low
9/24/2019B. RileyLower Price TargetBuy$57.50 ➝ $40.00Medium
9/12/2019GuggenheimInitiated CoverageBuy$40.00High
7/12/2019HC WainwrightSet Price TargetBuy$50.00Low
5/9/2019HC WainwrightReiterated RatingBuy$45.00Low
4/2/2019HC WainwrightSet Price TargetBuy$50.00Low
1/4/2019HC WainwrightSet Price TargetBuy$50.00Medium
10/16/2018B. RileyBoost Price TargetBuy ➝ Buy$50.00 ➝ $60.00High
10/1/2018HC WainwrightReiterated RatingBuy$45.00Low
9/13/2018HC WainwrightReiterated RatingBuy$27.50Medium
9/6/2018HC WainwrightSet Price TargetBuy$30.00Low
8/2/2018HC WainwrightSet Price TargetBuy$30.00Low
7/27/2018HC WainwrightSet Price TargetBuy$30.00Low
6/26/2018HC WainwrightReiterated RatingBuy$25.00Medium
5/9/2018HC WainwrightSet Price TargetBuy$30.00High
4/13/2018HC WainwrightReiterated RatingBuy$30.00Medium
4/2/2018HC WainwrightSet Price TargetBuy$30.00N/A
3/20/2018HC WainwrightSet Price TargetBuy$50.00Medium
2/8/2018HC WainwrightSet Price TargetBuy$50.00High
1/9/2018HC WainwrightReiterated RatingBuy$50.00Low
12/15/2017HC WainwrightSet Price TargetBuy$50.00High
12/15/2017B. RileySet Price TargetBuy$50.00Medium
12/11/2017Northland SecuritiesReiterated RatingBuy$100.00Medium
12/4/2017B. RileySet Price TargetBuy$50.00Medium
11/8/2017HC WainwrightReiterated RatingBuy$50.00N/A
11/8/2017LaidlawInitiated CoverageBuy$50.00N/A
10/11/2017HC WainwrightSet Price TargetBuy$50.00N/A
9/27/2017HC WainwrightReiterated RatingBuy$50.00Low
9/12/2017HC WainwrightReiterated RatingBuy$50.00Medium
7/11/2017HC WainwrightSet Price TargetBuy$50.00High
6/24/2017HC WainwrightSet Price TargetBuy$80.00High
6/14/2017LADENBURG THALM/SH SHSet Price TargetBuy$130.00Medium
6/14/2017HC WainwrightSet Price TargetBuy$80.00Medium
6/14/2017Northland SecuritiesSet Price TargetBuy$100.00Medium
6/14/2017(FBRC)Reiterated RatingBuyHigh
5/30/2017HC WainwrightReiterated RatingBuy$80.00High
5/30/2017Rodman & RenshawInitiated CoverageBuy$80.00High
5/15/2017(FBRC)Reiterated RatingOutperform$70.00Medium
12/6/2016(FBRC)Reiterated RatingOutperform$70.00N/A
8/10/2016(FBRC)Reiterated RatingBuyN/A
(Data available from 7/25/2016 forward)
EyePoint Pharmaceuticals logo
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor that is in Phase 1 clinical trials for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Read More

Today's Range

Now: $8.24
Low: $8.00
High: $8.52

50 Day Range

MA: $8.96
Low: $7.51
High: $9.88

52 Week Range

Now: $8.24
Low: $3.51
High: $15.06


105,886 shs

Average Volume

280,890 shs

Market Capitalization

$236.82 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of EyePoint Pharmaceuticals?

The following Wall Street analysts have issued reports on EyePoint Pharmaceuticals in the last year: B. Riley, Cantor Fitzgerald, Cowen Inc, HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for EYPT.

What is the current price target for EyePoint Pharmaceuticals?

4 Wall Street analysts have set twelve-month price targets for EyePoint Pharmaceuticals in the last year. Their average twelve-month price target is $17.63, suggesting a possible upside of 113.9%. Cowen Inc has the highest price target set, predicting EYPT will reach $25.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $8.50 for EyePoint Pharmaceuticals in the next year.
View the latest price targets for EYPT.

What is the current consensus analyst rating for EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EYPT will outperform the market and that investors should add to their positions of EyePoint Pharmaceuticals.
View the latest ratings for EYPT.

What other companies compete with EyePoint Pharmaceuticals?

How do I contact EyePoint Pharmaceuticals' investor relations team?

EyePoint Pharmaceuticals' physical mailing address is 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472. The company's listed phone number is 617-926-5000 and its investor relations email address is [email protected] The official website for EyePoint Pharmaceuticals is